文献速递血液净化与透析水电解质与酸碱

新型烟酰胺缓释制剂治疗血液透析患者难治性高磷血症的疗效与安全性:一项随机临床试验

Efficacy and Safety of a Novel Nicotinamide Modified-Release Formulation in the Treatment of Refractory Hyperphosphatemia in Patients Receiving Hemodialysis-A Randomized Clinical Trial.
PubMed 文献 · Kidney Int Rep · 2020-12-19

这项跨国随机双盲安慰剂对照研究评估了烟酰胺缓释制剂(NAMR)联合口服磷结合剂在血清磷酸盐>4.5 mg/dl的血液透析患者中的疗效与安全性。意向治疗人群包括NAMR组539例和安慰剂组183例,每日口服一次250-1500 mg/d。12周确认性分析显示NAMR组血清磷酸盐较安慰剂组显著降低0.51 mg/dl(95%CI -0.72,-0.29;P<0.0001),并伴随iPTH和钙化倾向改善,但腹泻和瘙痒更常见。

要点

  • NAMR联合磷结合剂可显著降低血透患者血清磷酸盐水平。
  • NAMR组iPTH和钙化倾向(T50时间)较安慰剂组显著改善。
  • NAMR组腹泻和瘙痒发生率高于安慰剂组。

核心结论

  • NAMR联合口服磷结合剂可显著改善血液透析患者的磷酸盐控制。

研究设计与样本

  • 跨国随机双盲安慰剂对照研究,纳入血清磷酸盐>4.5 mg/dl且使用磷结合剂的血液透析患者。
  • 意向治疗人群为NAMR组539例和安慰剂组183例,每日口服一次250-1500 mg/d。
  • 第一阶段为12周疗效验证期,期间不允许调整相关合并用药。

主要发现

  • 12周后NAMR组血清磷酸盐较安慰剂组显著降低0.51 mg/dl(95%CI -0.72,-0.29;P<0.0001)。
  • NAMR组iPTH为292.4±300.4 pg/ml,安慰剂组为337.0±302.7 pg/ml(P=0.04)。
  • NAMR组T50时间为23.8±97.1分钟,安慰剂组为2.3±100.7分钟(P=0.02)。
  • NAMR组腹泻和瘙痒较安慰剂组更常见。

临床怎么用

  • 对于使用磷结合剂仍存在高磷血症的血液透析患者,可考虑联合NAMR以改善磷酸盐控制。
  • 使用NAMR时需关注腹泻和瘙痒等不良反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Despite widespread use of phosphate binders (PBs), phosphate control is insufficient in many hemodialysis patients. Preliminary clinical observations suggest that nicotinamide may act synergistically with PBs to improve phosphate control. METHODS: This multinational, randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of nicotinamide modified release (NAMR) in combination with oral PB in a large cohort of hemodialysis patients with abnormal serum phosphate concentration (>4.5 mg/dl) despite treatment with PB. Patients entered a proof-of-efficacy phase (12 weeks [W12]) in which adjustments of relevant comedication were not permitted, followed by a safety extension phase for up to 52 weeks. Here, we report the results of the first phase. RESULTS: The intention-to-treat (ITT) population consisted of 539 patients in the NAMR and 183 patients in the placebo group. NAMR and placebo were orally administered once daily (250-1500 mg/d). Mean age of patients was 61.8 years, and 63.0% were men. In the confirmatory analysis that estimated the difference in serum phosphate concentration after 12 weeks, NAMR proved superior over placebo with a significant difference of -0.51 mg/dl (95% confidence interval [CI] -0.72, -0.29; P < 0.0001). This effect was associated with significantly lower intact parathyroid hormone (iPTH) values (NAMR: 292.4±300.4 pg/ml vs. placebo: 337.0±302.7 pg/ml; P = 0.04) and an improved calcification propensity (T50 time; NAMR: 23.8±97.1 minutes vs. placebo: 2.3±100.7 minutes; P = 0.02). Diarrhea and pruritus were more frequent in the NAMR group. CONCLUSION: NAMR combined with oral PB significantly improved phosphate control in hemodialysis patients.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Ketteler M, Wiecek A, Rosenkranz AR, et al. Efficacy and Safety of a Novel Nicotinamide Modified-Release Formulation in the Treatment of Refractory Hyperphosphatemia in Patients Receiving Hemodialysis-A Randomized Clinical Trial. Kidney Int Rep. 2020. PMID: 33732974. doi:10.1016/j.ekir.2020.12.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。